NEW YORK (GenomeWeb) – Bioinformatics firm BioDiscovery and genomic service provider Akesogen today announced a co-marketing deal, which they said will provide customers a complete end-to-end solution for cytogenomic array and next-generation sequencing services.
Financial and other terms of the deal were not disclosed.
As part of the agreement, samples obtained from Akesogen's laboratory will be analyzed with BioDiscovery's software solutions, "allowing users to easily process their samples and convert raw data into meaningful results," the partners said in a statement.
"We believe that our quality data-generation capabilities perfectly complement BioDiscovery's informatics solutions," Akesogen Chief Scientific Officer Mark Bouzyk said in a statement.
Based in Atlanta, Akesogen provides genomics, genetics, and biobanking services for clinical trials, diagnostic clinical testing, and research. BioDiscovery, headquartered in Hawthorne, California, develops software products for life science research and clinical applications.